Prescription Drug News and Research RSS Feed - Prescription Drug News and Research

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. [More]
Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc. [More]
Astellas, Medivation announce acceptance of XTANDI sNDA for review by FDA

Astellas, Medivation announce acceptance of XTANDI sNDA for review by FDA

Astellas Pharma Inc. and Medivation, Inc. today announced that the U.S. Food and Drug Administration has accepted for review a supplemental New Drug Application (sNDA) that they have submitted for XTANDI (enzalutamide) capsules in metastatic castration-resistant prostate cancer (mCRPC), which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication. [More]
Research: Adenosine deaminase may help activate immune system against HIV

Research: Adenosine deaminase may help activate immune system against HIV

New research findings published in the February 2016 issue of the Journal of Leukocyte Biology, suggest that a new therapeutic strategy for HIV may already be available by repurposing an existing prescription drug. [More]
Temple University Hospital makes strides in confronting prescription drug abuse

Temple University Hospital makes strides in confronting prescription drug abuse

Prescription drug abuse has become a public health crisis in the U.S., and Temple University Hospital has made strides in confronting this critical situation. [More]
Meridian Health Plan named one of 'Best and Brightest Companies to Work For'

Meridian Health Plan named one of 'Best and Brightest Companies to Work For'

Meridian Health Plan, for the second time, has been nationally named one of the "Best and Brightest Companies to Work For" by the National Association for Business Resources. Previously, the NABR had consistently named Meridian as one of "Metropolitan Detroit's 101 Best and Brightest Companies to Work For" 2012 through 2015. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Nearly 7 in 10 middle and high school students exposed to e-cigarette ads

Nearly 7 in 10 middle and high school students exposed to e-cigarette ads

About 7 in 10 middle and high school students – more than 18 million young people – see e-cigarette advertising in stores, online, in newspapers and magazines, or on television and in movies, according to a new CDC Vital Signs report. [More]
Most patients with chronic pain continue to receive prescription opioids after nonfatal overdose

Most patients with chronic pain continue to receive prescription opioids after nonfatal overdose

A study led by Boston Medical Center indicates that most patients with chronic pain who are hospitalized after a nonfatal opioid overdose continue to receive prescription opioids after the overdose and are at high risk for experiencing a repeated overdose. [More]
Opioid prescribing guideline has immediate, sustained impact on prescribing rates

Opioid prescribing guideline has immediate, sustained impact on prescribing rates

Emergency medicine physicians at Temple University Hospital have found that an opioid prescribing guideline had an immediate and sustained impact on opioid prescribing rates for minor conditions and chronic noncancer pain in an acute care setting. [More]
Harmony Health Plan of Illinois to donate $10,000 to Kidz Korna

Harmony Health Plan of Illinois to donate $10,000 to Kidz Korna

Harmony Health Plan of Illinois, Inc., a subsidiary of WellCare Health Plans, Inc. (NYSE: WCG), will give $10,000 to Kidz Korna to help make the holidays special for 10,000 low-income children in Chicago's Englewood community. [More]
Young teens more vulnerable to opioid addiction, study reveals

Young teens more vulnerable to opioid addiction, study reveals

A Michigan State University study shows that 14- and 15-year-olds are at a higher risk of becoming dependent on prescription drugs within a 12-month period after using them extra-medically, or beyond the prescribed amount. [More]
New survey shows how patients, pharmacists benefit from med sync programs

New survey shows how patients, pharmacists benefit from med sync programs

A recent survey of National Community Pharmacists Association member pharmacies utilizing NCPA's Simplify My Meds (SMM) program documented how both patients and pharmacists benefit from medication synchronization programs, or "med sync." [More]
HealthCare Partners Medical Group receives IHA Medicare Advantage 4.5 Star Award

HealthCare Partners Medical Group receives IHA Medicare Advantage 4.5 Star Award

DaVita HealthCare Partners, a leading independent medical group in America and leading provider of kidney care services, today announced that HealthCare Partners Medical Group has received the Integrated Healthcare Association's Medicare Advantage 4.5 Star Award. [More]
New data shows opioid overdose deaths hit record levels in 2014

New data shows opioid overdose deaths hit record levels in 2014

From 2000 to 2014 nearly half a million Americans died from drug overdoses. Opioid overdose deaths, including both opioid pain relievers and heroin, hit record levels in 2014, with an alarming 14 percent increase in just one year, according to new data published today in CDC's Morbidity and Mortality Weekly Report. [More]
Variant signs worldwide exclusive license and development agreement with L&F Research

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200. [More]
Stanford study finds that overprescription of opioids goes beyond ‘pill mill’ prescribers

Stanford study finds that overprescription of opioids goes beyond ‘pill mill’ prescribers

Most prescriptions for opioid painkillers are made by the broad swath of U.S. general practitioners, not by a limited group of specialists, according to a study by researchers at the Stanford University School of Medicine. [More]

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection. [More]
New guidelines may help reduce medication use among seniors

New guidelines may help reduce medication use among seniors

We're not getting any younger. According to the Administration for Community Living, by 2060, there will be about 98 million older persons in the United States — more than twice their number in 2013. [More]
Economic and racial barriers impact treatment of moderate to severe psoriasis

Economic and racial barriers impact treatment of moderate to severe psoriasis

In the first known study to examine the prevalence and treatment of psoriasis in older Americans, experts from the Perelman School of Medicine at the University of Pennsylvania have found that black patients receiving Medicare are less likely to receive biologic therapies -medications derived from human or animal cells or tissues - for the treatment of moderate to severe psoriasis than white patients. [More]